Dr Michael D. Jain, lymphoma expert at the University of South Florida and H. Lee Moffitt Cancer Center and Research Institute, discusses potentially practice-changing data in the management of non-Hodgkin lymphoma from the ASCO 2020 virtual annual meeting.
Highlights include a presentation on ZUMA-5, the latest in the ZUMA series of trials of CAR T cells in relapsed/refractory lymphoma. Here, as in the earlier trials, axicabtagene ciloleucel achieved a significant and durable benefit.
Next, Dr Jain looks at phase 1/2 trial data on the first CD19/22 dual-targeting CAR T-cell therapy, here used in combination with pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma. Responses to the dual-targeting CAR T approach were comparable to those of previous CAR T studies and were associated with a good safety profile.
In the CAR T-cell era, the question arises as to whether a stem cell transplant is appropriate in patients who relapse on chemo-immunotherapy and whether the timing of the transplant affects outcomes. Dr Jain believes that the results of a CIBMTR registry study answering these questions could be practice-changing.
Finally, Dr Jain discusses a phase 2 study that examined the combination of Bcl-2 inhibition and chemoimmunotherapy in Richter syndrome, which is associated with a poor prognosis. Although it is a small study, 65% of patients achieved a complete response. Dr Jain suggests that this strategy may prove a viable option before turning to the use of whole-brain radiotherapy in primary CNS lymphoma.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Highlights in Non-Hodgkin Lymphoma From ASCO 2020 - Medscape - Jun 23, 2020.
Comments